Not Yet Recruiting PHASE3 INTERVENTIONAL 1-arm
NCT07129759
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
A Long-term Extension Study to Evaluate the Safety and Tolerability of Daily Oral LUM-201 in Children With Growth Hormone Deficiency (GHD)
Sponsor: Lumos Pharma
Conditions
Growth Hormone Deficiency (GHD)
Interventions
LUM-201
Updated 1 time since 2025 Last updated: Aug 15, 2025 Started: Sep 30, 2026 Primary completion: Feb 28, 2030 Completion: Feb 28, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE3 clinical study on Growth Hormone Deficiency (GHD), this trial is actively recruiting participants. The trial is conducted by Lumos Pharma and has accumulated 1 data snapshot since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Lumos Pharma
Data source: Lumos Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.